Matchpoint Closes 150 Million Dollar Series B

Company Matchpoint Therapeutics Event Type Series B financing Modality Precision covalent small molecule (oral) Asset MPT-062 Target Undisclosed (T-cell modulator) Disease Area Autoimmune and inflammatory disease Summary Matchpoint Therapeutics closed a $150 million Series B to advance precision covalent small molecules for autoimmune and inflammatory…